A Lincoln University study says it is too early to forecast what economic benefits - if any - are to be gained from New Zealand establishing a commercial biopharming industry. Biopharming - the production of pharmaceuticals compounds from genetically modified crops and livestock – is touted by some as an emerging success story in both agriculture and the pharmaceutical industry. Its advocates say biopharming has the potential to dramatically cut the cost of manufacturing compounds used in medicine, food manufacturing and dietary supplements.